Janssen, work­ing to­gether to­ward health­ier fu­ture

Shanghai Daily - - CIIE -

The China In­ter­na­tional Im­port Expo is be­ing hailed for bring­ing more op­por­tu­ni­ties to carry out in-depth con­ver­sa­tion with gov­ern­ments, en­ter­prises and other stake­hold­ers and jointly dis­cuss the devel­op­ment of the health care in­dus­try. Xi’an Janssen, a John­son & John­son sub­sidiary, is very pleased to show­case in­no­va­tive prod­ucts and tech­nolo­gies to the world, and it is ready to take a new step in phar­ma­ceu­ti­cal man­u­fac­tur­ing and help serve the rapidly ex­pand­ing needs of China.

“Since our found­ing in 1985, Xi’an Janssen has strived to be a leader in China’s health care in­dus­try,” As­gar Ran­goon­wala, Pres­i­dent of Xi’an Janssen and mem­ber of the John­son & John­son China Pres­i­dent’s Coun­cil, said. “Since re­form and open­ing, we are con­tin­u­ing to build on the long, proud her­itage in China, and re­mains com­mit­ted to de­liv­er­ing trans­for­ma­tional health care prod­uct and ser­vice that ad­dress un­met needs, to pa­tients and con­sumers in China. We now feel that China is poised to trans­form health care glob­ally, as a con­flu­ence of fac­tors — in­vest­ment, ar­ti­fi­cial in­tel­li­gent, cloud com­put­ing, big data and far-sighted gov­ern­ment poli­cies — are cre­at­ing an en­vi­ron­ment where in­no­va­tion will im­prove health out­comes and qual­ity of life.”

Ran­goon­wala added that “we hope to cap­i­tal­ize on our more than 30 years of devel­op­ment in China, and that we can strengthen ex­change and co­op­er­a­tion with a wide range of Chi­nese health care play­ers. The expo will pro­vide a wealth of in­sight into China’s plans to foster in­ter­na­tional trade and the in­ter­na­tion­al­iza­tion of China’s mar­ket out­look.”

John­son & John­son is the world’s most com­pre­hen­sive and broadly-based man­u­fac­turer of health care prod­ucts.

By 2017, it had es­tab­lished 15 le­gal en­ti­ties and set up pro­duc­tion bases for all busi­ness ar­eas, with over 10,000 em­ploy­ees spread­ing over 90 cities and con­trib­uted 75 bil­lion yuan (US$10.7 bil­lion) to China’s econ­omy.

In 1985, the Janssen Phar­ma­ceu­ti­cal Com­pa­nies of John­son & John­son first es­tab­lished its op­er­a­tions in China through a man­u­fac­tur­ing fa­cil­ity — Xi’an Janssen. Now, it is one of the ear­li­est multi­na­tional phar­ma­ceu­ti­cal com­pa­nies that trail­blazed in China.

Fol­low­ing an in­vest­ment of US$397 mil­lion, the new Janssen sup­ply chain in­no­va­tion hub in Xi’an is set to open by the sec­ond half of 2019, set­ting a new stan­dard in phar­ma­ceu­ti­cal man­u­fac­tur­ing in China and help­ing to serve the rapidly ex­pand­ing needs of the coun­try and other mar­kets in Asia Pa­cific.

“We hope to es­tab­lish a brand­new phar­ma­ceu­ti­cal in­no­va­tion model through in­ter­na­tional and lo­cal co­op­er­a­tion and jointly com­mit to the re­search and devel­op­ment of in­no­va­tive drugs to pro­mote the devel­op­ment of lo­cal new drug ca­pa­bil­i­ties,” Ran­goon­wala told Shang­hai Daily.

Shang­hai’s as­pi­ra­tion for a global in­no­va­tion hub has cre­ated a pos­i­tive en­vi­ron­ment and ecosys­tem for in­no­va­tion, and it has at­tracted tal­ent as well. The city will un­doubt­edly be Xi’an Janssen’s bridge to fur­ther pro­mote in­no­va­tion in China.

The Janssen China Dis­cov­ery Cen­ter, one of the R&D cen­ters in Shang­hai, moved into a new, sig­nif­i­cantly larger and welle­quipped lab­o­ra­tory space in the Zhangjiang Hi-Tech Park last year.

As one of Janssen’s four global R&D hubs, the Dis­cov­ery Cen­ter is en­gaged in drug re­search for lung can­cer, hep­ati­tis B and hema­to­logic ma­lig­nan­cies. Its team of over 60 sci­ence pro­fes­sion­als is run­ning 10 projects with the aim of de­liv­er­ing one clin­i­cal can­di­date per year.

Mean­while, the in­cu­ba­tor plat­form of John­son & John­son, JLABS, will open in early 2019. As a col­lab­o­ra­tion with the city gov­ern­ment and the Pudong New Area gov­ern­ment, it will be the first JLABS lo­ca­tion out­side North Amer­ica and will ac­com­mo­date up to 50 life sci­ence and health care star­tups fo­cused on in­no­va­tions across the en­tire health care spec­trum, in­clud­ing phar­ma­ceu­ti­cals, med­i­cal de­vices and the con­sumer sec­tor.

By tak­ing such ef­forts to aid en­trepreneur­ship, Xi’an Janssen is push­ing for­ward in­no­va­tion strate­gies and for­ward-look­ing in­vest­ment mod­els to en­able the dis­cov­ery of game-chang­ing medicines in China.

His­tor­i­cally, 50 per­cent of Janssen’s medicines have been the re­sult of ex­ter­nal col­lab­o­ra­tion. Ran­goon­wala said that it is vi­tal for an in­no­va­tion-ori­ented en­ter­prise like Janssen to keep on spot­ting tal­ent and seek­ing col­lec­tive devel­op­ment on a global scale.

“We fo­cus on the high­est un­met med­i­cal needs, iden­tify the best sci­ence — in­ter­nal or ex­ter­nal — and lever­age the scale and reach of our global devel­op­ment or­ga­ni­za­tions to de­velop, file and launch in­no­va­tive medicines glob­ally,” said Ran­goon­wala.

In re­cent years, the gov­ern­ment has taken mul­ti­ple pos­i­tive steps to fur­ther open its doors to global in­vest­ment and foster new mod­els of phar­ma­ceu­ti­cal in­no­va­tion. Ran­goon­wala ex­pressed Janssen’s as­pi­ra­tion to be­come a lead­ing global phar­ma­ceu­ti­cal in­no­va­tor, who has al­ready been seiz­ing the op­por­tu­ni­ties pro­vided by the re­cent re­forms in China mar­ket.

“Since 2017, Xi’an Janssen has been granted 11 ap­provals for new prod­ucts/in­di­ca­tions and three line-ex­ten­sions, for in­no­va­tive prod­ucts,” said Ran­goon­wala. “In 2018, Xi’an Janssen has made sig­nif­i­cant progress driven by a strong prod­uct pipe­line and mar­ket ex­pan­sion ini­tia­tives in 2018, and en­vi­sion­ing our strong­est growth in the re­cent 20 years.”

As China tran­si­tions to­wards a new era un­der its Healthy China 2030 Ini­tia­tive cre­at­ing more op­por­tu­ni­ties and chal­lenges for play­ers in the in­dus­try, Janssen also seeks to strengthen its part­ner­ship with China by con­tin­u­ing to lay down strong roots through on­go­ing in­vest­ment in its in­no­va­tion and man­u­fac­tur­ing fa­cil­i­ties.

“The prin­ci­ples of ‘Healthy China 2030’ are in align­ment with our global Healthy So­ci­ety Ini­tia­tive, which builds on our global reach and scale in or­der to sup­port the devel­op­ment of a sus­tain­able healthy fu­ture,” Ran­goon­wala said of his vi­sion for the fu­ture Chi­nese health in­dus­try.

“It brings to­gether our work in cor­po­rate cit­i­zen­ship, in­no­va­tion, thought lead­er­ship and sup­port of pub­lic health and health care work­ers.”

As­gar Ran­goon­wala, pres­i­dent of Xi’an Janssen, mem­ber of the John­son & John­son China Pres­i­dents’ Coun­cil

Newspapers in English

Newspapers from China

© PressReader. All rights reserved.